Nigrostriatal reduction of aromatic L-amino acid decarboxylase activity in MPTP-treated squirrel monkeys: In vivo and in vitro investigations

Journal of Neurochemistry

Volumn 74, Issue 3, 2000, Pages 1147-1157

  Yee, R E ^a   Huang, S C ^a   Stout, D B ^a   Irwin, I ^b   Shoghi Jadid, K ^a   Togaski, D M ^b   Delanney, L E ^b   Langston, J W ^b   Satyamurthy, N ^a   Farahani, K F ^a   Phelps, M E ^a   Barrio, J R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PARKINSON S INSTITUTE   (United States)

Author keywords

1 Methyl 4 phenyl 1,2,3,6 tetrahydropyridine; 6 18F Fluoro L DOPA; Aromatic L amino acid decarboxylase; Squirrel monkeys

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AROMATIC LEVO AMINO ACID DECARBOXYLASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; DECARBOXYLATION; ENZYME ACTIVITY; FEMALE; MALE; NERVE CELL DEGENERATION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; SQUIRREL MONKEY; SUBSTANTIA NIGRA;

ANIMALIA; SAIMIRI; SCIURIDAE;

EID: 0033972521     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2000.741147.x     Document Type: Article

References (78)

1. Arai R., Karasawa N., Geffard M., Nagatsu T., and Nagatsu I. (1994) Immunohistochemical evidence that central serotonin neurons produce dopamine from exogenous L-DOPA in the rat, with reference to the involvement of aromatic L-amino acid decarboxylase. Brain Res. 667, 295-299.
2. Awapara J. and Saine S. (1975) Fluctuations in DOPA decarboxylase activity with age. J. Neurochem. 24, 817-818.
3. 18F]Fluoro-L-DOPA probes dopamine turnover rates in central dopaminergic structures. J. Neurosci. Res. 27, 487-493.
4. Barrio J. R., Huang S.-C., Yu D.-C., Melega W. P., Quintana J., Cherry S. R., Jacobson A., Namavari M., Satyamurthy N., and Phelps M. E. (1996) Radiofluorinated L-m-tyrosines: new in-vivo probes for central dopamine biochemistry. J. Cereb. Blood Flow Metab. 16, 667-678.
5. Barrio J. R., Huang S.-C, and Phelps M. E. (1997) Biological imaging and the molecular basis of dopaminergic disease. Biochem. Pharmacol. 54, 341-348.
6. Borri Voltattorni C., Minelli A., and Turano C. (1971) Spectral properties of the coenzyme bound to dopa decarboxylase from pig kidney. FEBS Lett. 17, 231-235.
7. Bowsher R. R. and Henry D. P. (1986) Aromatic-L-amino acid decarboxylase: biochemistry and functional significance, in Neuromethods, Series 1: Neurochemistry, Neurotransmitter Enzymes (Boulton A. A., Baker G. B., and Yu P. H., eds), pp. 33-77. Humana Press, Clifton, New Jersey.
8. Broch O. J. Jr. and Fonnum F. (1972) The regional and subcellular distribution of catechol-O-methyltransferase in the rat brain. J. Neurochem. 19, 2049-2055.
9. Burns R. S., Chiueh C. C., Markey S. P., Ebert M. H., Jacobowitz D. M., and Kopin I. J. (1983) A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by W-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Nail. Acad. Sci. USA 80, 4546-4550.
10. 18F]fluoro-L-DOPA/PET scans in non-human primates. Life Sci. 21, 1759-1766.
11. Cheramy A., Nieoullon A., and Glowinski J. (1978) In vivo changes in dopamine release in cat caudate nucleus and substantia nigra induced by nigral application of various drugs including GABAergic agonists and antagonists, in Interactions Between Putative Neurotransmitters in the Brain (Garattini S., Pujol J. F., and Saminin R., eds), pp. 175-190. Raven Press, New York.
12. Cho S., Duchemin A. M., Neff N. H., and Hadjiconstantinou M. (1999) Tyrosine hydroxylase, aromatic L-amino acid decarboxylase and dopamine metabolism after chronic treatment with dopaminergic drugs. Brain Res. 830, 237-245.
13. Christenson J. G., Dairman W., and Udenfriend S. (1970) Preparation and properties of a homogeneous aromatic L-amino acid decarboxylase from hog kidney. Arch. Biochem. Biophys. 141, 356-367.
14. Cumming P. and Gjedde A. (1998) Compartmental analysis of DOPA decarboxylation in living brain from dynamic positron emission tomograms. Synapse 29, 37-61.
15. 18F-fluorodopa in the hooded rat. Biochem. Pharmacol. 2, 247-250.
16. 18F]fluoro-L-dihydroxyphenylalanine metabolism in the rat. J. Neurochem. 63, 1675-1682.
17. Cumming P., Kuwabara H., Ase A., and Gjedde A. (1995) Regulation of DOPA decarboxylase activity in brain of living rat. J. Neurochem. 65, 1381-1390.
18. Cumming P., Ase A., Laliberté C., Kuwabara H., and Gjedde A. (1997) In vivo regulation of dopa decarboxylase by dopamine receptors in rat brain. J. Cereb. Blood Flow Metab. 17, 1254-1260.
19. Doteuchi M., Wang C., and Costa E. (1974) Compartmentation of dopamine in rat striatum. Mol. Pharmacol. 10, 225-234.
20. Elsworth J. D., Deutch A. Y., Redmond D. E., Sladek J. R., and Roth R. H. (1987) Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on catecholamines and metabolites in primate brain and CSF. Brain Res. 415, 293-299.
21. Forno L. S., DeLanney L. E., Irwin I., and Langsten J. W. (1993) Similarities and differences between MPTP-induced parkinsonism and Parkinson's disease. Neuropathologic considerations. Adv. Neurol. 60, 600-608.
22. German D. C., Dubach M., Askari S., Speciale S. G., and Bowden D. M. (1988) 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonian syndrome in Macaco fascicularis: which midbrain dopaminergic neurons are lost? Neuroscience 24, 161-174.
23. Gjedde A., Reith J., Dyne S., Léger G., Guttman M., Diksic M., Evans A., and Kuwabara H. (1991) Dopa decarboxylase of the human brain. Proc. Natl. Acad. Sci. USA 88, 2721-2725.
24. Gjedde A., Léger G. C., Cumming P., Yasuhara Y., Evans A. C., Guttman M., and Kuwabara H. (1993) Striatal L-DOPA decarboxylase activity in Parkinson's disease in vivo: implications for the regulation of dopamine synthesis. J. Neurochem. 61, 1538-1541.
25. Glowinski J. (1973) Brain, Nerves and Synapses, Vol. 4: Pharmacology and the Future of Man, pp. 204-214. Karger, Basel.
26. 14C]serotonin in the striatum. J. Neurochem. 16, 645-653.
27. Groppetti A., Algeri S., Cattabeni F., Di Giulio A. M., Galli C. L., Ponzio F., and Spano P. F. (1977) Changes in specific activity of dopamine metabolites as evidence of multiple compartmentation of dopamine in striatal neurons. J. Neurochem. 28, 193-197.
28. Hartvig P., Tedroff J., Lindner K. J., Burling P., Chang C.-W., Tsukada H., Watanabe Y., and Långström B. (1993) Positron emission tomographic studies on aromatic L-amino acid decarboxylase activity in vivo for L-DOPA and 5-hydroxy-L-tryptophan in the monkey brain. J. Neural Transm. 94, 127-135.
29. Hayashi S., Murakami Y., and Matsufuji S. (1996) Ornithine decarboxylase antizyme: a novel type of regulatory protein. Trends Biochem. Sci. 21, 27-30.
30. Hefti F., Melamed E., and Wurtman R. J. (1980) Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization. Brain Res. 195, 123-137.
31. Hoffman J. M., Melega W. P., Hawk T. C., Grafton S. C., Luxen A., Mahoney D. K., Barrio J. R., Huang S.-C., Mazziotta J. C., and Phelps M. E. (1992) The effects of carbidopa administration on 6-[F-18]fluoro-L-dopa kinetics in PET studies. J. Nucl. Med 33, 1472-1477.
32. Hornykiewicz O. (1966) Dopamine (3-hydroxytyramine) and brain function. Pharmacol. Rev. 18, 925-964.
33. 18F]Fluoro-L-DOPA metabolism in living human brain: a comparison of six analytical methods. J. Cereb. Blood Flow Metab. 13, 57-69.
34. 18F]fluoro-DOPA in human positron emission tomographic studies. J. Cereb. Blood Flow Metab. 11, 898-913.
35. Huang S.-C., Barrio J. R., Yu D.-C., Chen B., Grafton S., Melega W. P., Hoffman J. M., Satyamurthy N., Mazziotta J. C., and Phelps M. E. (1991A) Modelling approach for separating blood time-activity curves in positron emission tomographic studies. Phys. Med. Biol. 36, 749-761.
36. Huang S.-C., Stout D. B., Yee R. E., Satymurthy N., and Barrio J. R. (1998) Distribution volume of radiolabeled large neutral amino acid in brain tissue. J. Cereb. Blood Flow Metab. 18, 1288-1293.
37. Irwin I., Delanney L. E., Forno L. S., Finnegan K. T., Di Monte D. A., and Langston J. W. (1990) The evolution of nigrostriatal neurochemical changes in the MPTP-treated squirrel monkey. Brain Res. 531, 242-252.
38. Ishikawa T., Dhawan V., Chaly T., Margouleff C., Robeson W., Dahl J. R., Mandel F., Spetsieris P., and Eidelberg D. (1996) Clinical significance of Striatal DOPA decarboxylase activity in Parkinson's disease. J. Nucl. Med. 37, 216-221.
39. Joh T. H., Hwang O., and Abate C. (1986) Phenylalanine hydroxylase, tyrosine hydroxylase, and tryptophan hydroxylase, in Neuromethods, Series 1: Neurochemistry, Neurotransmitter Enzymes (Boulton A. A., Baker G. B., and Yu P. H., eds), pp. 1-23. Humana Press, Clifton, New Jersey.
40. Katz I. R. (1980) Inhibition of 3,4-dihydroxy-L-phenylalanine decarboxylase in rat Striatal synaptosomes by amino acids interacting with substrate transport. Biochim. Biophys. Acta 600, 195-204.
41. Keen R. E., Barrio J. R., Huang S. C., Hawkins R. A., and Phelps M. E. (1989) In vivo cerebral protein synthesis rates with leucyl-transfer RNA used as a precursor pool: determination of biochemical parameters to structure tracer kinetic models for positron emission tomography. J. Cereb. Blood Flow Metab. 9, 429-445.
42. Keeping E. S. (1995) Introduction to Statistical Inference, pp. 193-197. Dover, New York.
43. Kilpatrick I. C., Jones M. W., and Phillipson O. T. (1986) A semiautomated analysis method for catecholamines, indoleamines, and some prominent metabolites in microdissected regions of the nervous system: an isocratic HPLC technique employing coulometric detection and minimal sample preparation. J. Neurochem. 46, 1865-1876.
44. Kish S. J., Shannak K., and Hornykiewicz O. (1988) Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N. Engl. J. Med. 318, 876-880.
45. Kish S. J., Zhong X. H., Hornykiewicz. O., and Haycock J. W. (1995) Striatal 3,4-dihydroxyphenylalamine in aging: disparity between postmortem and positron emission tomography studies? Ann. Neurol. 38, 260-264.
46. Kozlowski M. R., Sawyer S., and Marshall J. F. (1980) Behavioural effects and supersensitivity following nigral dopamine receptor stimulation. Nature 287, 52-54.
47. Kuntzman R., Shore P. A., Bogdanshi D., and Brodie D. B. (1961) Microanalytical procedures for fluorometric assay of brain dopa-5HTP decarboxylase, norepinephrine, and serotonin, and a detailed mapping of decarboxylase activity in brain. J. Neurochem. 6, 226-232.
48. Kuwabara H., Cumming P., Yasuhara Y., Léger G. C., Guttman M., Diksic M., Evans A. C., and Gjedde A. (1995) Regional striatal DOPA transport and decarboxylase activity in Parkinson's disease. J. Nucl. Med. 36, 1226-1231.
49. Langston J. W., Forno L. S., Rebert C. S., and Irwin I. (1984) Selective nigral toxicity after systematic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) in the squirrel monkey. Brain Res. 292, 390-394.
50. Leenders K. L., Salmon E. P., Tyrrell P., Perani D., Brooks D. J., Sager H., Jones T., Marsden D., and Frackowick S. J. (1990) The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch. Neurol. 47, 1290-1298.
51. Lin K.-P., Huang S.-C, Baxter L. R., and Phelps M. E. (1994) A general technique for interstudy registration of multifunction and multimodality images. IEEE Trans. Nucl. Sci. 40, 2850-2855.
52. Lin K.-P., Huang S.-C., Yu D.-C, Melega W. P., Barrio J. R., and Phelps M. E. (1996) Automated image registration for FDOPA PET studies. Phys. Med. Biol. 41, 2775-2788.
53. Lloyd K. G. and Hornykiewicz O. (1972) Occurrence and distribution of aromatic L-amino acid (L-DOPA) decarboxylase in the human brain. J. Neurochem. 19, 1549-1559.
54. Mackay A. V. P., Davies P., Dewar A. J., and Yates C. M. (1978) Regional distribution of enzymes associated with neurotransmission by monoamines, acetylcholine, and GABA in the human brain. J. Neurochem. 30, 827-839.
55. McCaman R. E., McCaman M. W., Hunt J. M., and Smith M. S. (1965) Microdetermination of monoamine oxidase and 5HTP decarboxylase activity in nervous tissue. J. Neurochem. 12, 15-23.
56. Melamed E., Hefti F., Pettibone D. J., Liebman J., and Wurtman R. J. (1981) Aromatic L-amino acid decarboxylase in rat corpus striatum: implications for actions of L-DOPA in parkinsonism. Neurology 31, 651-655.
57. 18F]Fluoro-L-DOPA metabolism in MPTP-treated monkeys: assessment of tracer methodologies for positron emission tomography. Brain Res. 543, 271-276.
58. 18F]Fluoro-DOPA metabolism in monkeys and humans: biochemical parameters for the formulation of tracer kinetic models with positron tomography. J. Cereb. Blood Flow Metab. 11, 890-897.
59. Muenter M. D. and Tyce G. M. (1971) L-Dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side-effects. Mayo Clin. Proc. 46, 231-239.
60. Mura A., Jackson D., Manley M. S., Young S. J., and Groves P. M. (1995) Aromatic L-amino acid decarboxylase immunoreactive cells in the rat striatum: a possible site for the conversion of exogenous L-DOPA to dopamine. Brain Res. 704, 51-60.
61. Murakami Y., Tanahashi N., Tanaka K., Omura S., and Hayashi S. (1996) Proteasome pathway operates for the degradation of ornithine decarboxylase in intact cells. Biochem. J. 317, 77-80.
62. Mytilineou C., Cohen G., and Heikkila R. E. (1985) 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine is toxic to mesencephalic DA neurons in culture. Neurosci. Lett. 57, 19-24.
63. Nahmias C. and Wahl L. (1996) Modeling fluorine-18-6-fluoro-L-DOPA in humans. J. Nucl. Med. 37, 432-437.
64. 18F]6-fluoro-L-m-tyrosine in the human brain. Mov. Disord. 3, 298-304.
65. Neff N. H. and Hadjiconstantinou M. (1995) Aromatic L-amino acid decarboxylase modulation and Parkinson's disease. Prog. Brain Res. 106, 91-97.
66. Nyberg P., Nordberg A., Wester P., and Winblad B. (1983) Dopaminergic deficiency is more pronounced in putamen than in nucleus caudatus in Parkinson's disease. Neurochem. Pathol. 1, 193-202.
67. Pate B. D., Kawamata T., Yamada T., McGeer E. G., Hewitt K. A., Snow B. J., Ruth T., and Calne D. B. (1993) Correlation of striatal fluorodopa uptake in MPTP monkey with dopaminergic indices. Ann. Neurol. 34, 331-338.
68. Pifl C. H., Schingnitz G., and Hornykiewicz O. (1991) Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey. Neuroscience 44, 591-605.
69. Rahman M. K., Nagatsu T., and Kato T. (1981) Aromatic L-amino acid decarboxylase activity in central and peripheral tissues and serum of rats with DOPA and 5HTP as substrates. Biochem. Pharmacol. 30, 645-649.
70. 18F]fluoro-L-DOPA in rat. J. Cereb. Blood Flow Metab. 10, 707-719.
71. 3H-GABA release from slices of rat substantia nigra in vitro. Nature 268, 652-654.
72. Robertson G. S., Damsma G., and Fibiger H. C. (1991) Characterization of dopamine release in the substantia nigra by in vivo microdialysis in freely moving rats. J. Neurosci. 11, 2209-2216.
73. Rossor M. N., Watkins J., Brown M. J., Reid J. L., and Dollery C. T. (1980) Plasma levodopa, dopamine, and therapeutic response following levodopa therapy of Parkinson's patient. J. Neurol. Sci. 46, 385-392.
74. Scherman D., Desnos C., Darchen F., Pollak P., Javoy-Agid F., and Agid Y. (1989) Striatal dopamine deficiency in Parkinson's disease: role of aging. Ann. Neurol. 26, 551-557.
75. Stout D. B. (1999) Small monkeys as clinical models for the study of the central dopuminergic system using positron emission tomography. Ph.D. thesis. University of California, Los Angeles.
76. Stout D. B., Huang S.-C., Melega W. P., Raleigh M. J., Phelps M. E., and Barrio J. R. (1998) Effects of large neutral amino acid concentrations on 6-[F-18]fluoro-L-DOPA kinetics. J. Cereb. Blood Flow Metab. 18, 43-51.
77. 11C]DOPA disposition in the monkey brain. Brain Res. 713, 92-98.
78. 18F]fluoro-L-Dopa (FDOPA) striatal kinetics. (Ahstr.) Neuroimage 7, A14.